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Treatment With Highly Active Antiretroviral Therapy in Human
Immunodeficiency Virus Type 1–Infected Children Is Associated With a
Sustained Effect on Growth
Gwenda Verweel, MD*; Annemarie M. C. van Rossum, MD*; Nico G. Hartwig, MD, PhD*;
Tom F. W. Wolfs, MD, PhD‡; Henrie¨tte J. Scherpbier, MD§; and Ronald de Groot, MD, PhD*
ABSTRACT. Introduction. Growth failure is a com-
mon feature of children with human immunodeficiency
virus type 1 (HIV-1) infection. Children who are treated
with mono or dual nucleoside analogue reverse tran-
scriptase inhibitor (NRTI) therapy show a temporary in-
crease in weight gain and linear growth rate. In adults,
protease-inhibitor-containing antiretroviral therapy is as-
sociated with a sustained weight gain and increased
body mass index (BMI). Experience with protease inhib-
itors and growth in children is still limited. The data
mainly deal with short-term effects on growth.
Objective. To evaluate the effect of highly active an-
tiretroviral therapy (HAART) on growth in children with
HIV-1 infection.
Design and Methods. We analyzed selected growth
parameters, clinical data, and laboratory results as part of
a prospective, open, uncontrolled, multicenter study to
evaluate the clinical, immunologic, and virologic re-
sponse to HAART consisting of indinavir, zidovudine,
and lamivudine in children with HIV-1 infection. Height
and weight were measured at 0, 12, 24, 36, 48, 60, 72, 84,
and 96 weeks after initiation of HAART. Information
about the children’s growth before enrollment in the
study was retrieved from the hospital medical records
and/or the school doctor or health center. BMI was cal-
culated. z Scores were used to express the standard de-
viation (SD) in SD units from the Dutch reference curves
for age and gender. Viral loads and CD4 T-cell counts
were examined prospectively and related to these growth
parameters. z Scores were also calculated for CD4 T-cell
counts to correct for age-related differences. A z score of
0 represents the P50, which is exactly the age/sex-appro-
priate median. A height z score of 1 indicates that a
child’s height is 1 SD below the age- and gender-specific
median height for the normal population. Virologic re-
sponders were defined as those who either reached an
undetectable viral load (<500 copies/mL) or had a >1.5
log reduction in viral load compared with baseline at
week 12 after the initiation of HAART, which was main-
tained during the follow-up period.
Results. Patients. Twenty-four patients were in-
cluded (age: 0.4–16.3 years at baseline), with a median
HIV-1 RNA load of 105 925 copies/mL (5.03 log), a me-
dian CD4 T-cell count of 0.586  109/L (median z score:
2.28 SD), a median height z score of 1.22, a median
weight z score of 0.74, and a median baseline BMI z
score of 0.32. Eleven patients were naive to antiretrovi-
ral therapy, and 13 patients had received previous treat-
ment with NRTI monotherapy. Twenty children used
indinavir and 4 children used nelfinavir as part of
HAART.
Virologic and immunologic responses to HAART. Sev-
enteen children were virologic responders, and 7 chil-
dren were virologic nonresponders. In patients naive to
NRTIs, median baseline viral loads were significantly
higher than in pretreated patients. However, at weeks 48
and 96, there was no significant difference between the
viral loads of both groups. At baseline, there was no
significant difference in CD4 T-cell z scores between
virologic responders and nonresponders or between na-
ive and pretreated patients. During 96 weeks of HAART,
the increase of CD4 T-cell z score was significantly
higher in responders than in nonresponders. The in-
crease in CD4 T-cell z score was not significantly dif-
ferent for naive and pretreated patients.
Height, weight, and BMI z score changes. We found that
there was a trend toward a significantly increased z score
change during 96 weeks of HAART compared with the z
score change before HAART initiation for height and
weight, but not for BMI.
Growth and virologic response to HAART. When the
data were analyzed separately for virologic responders
and nonresponders, virologic responders showed signif-
icant increases in height and weight. The height and
weight of virologic nonresponders did not change signif-
icantly. The BMI did not change significantly in respond-
ers or in nonresponders.
Growth and immunologic response to HAART. The in-
crease of weight and BMI z scores from baseline corre-
lated positively with the CD4 T-cell z score increase
from baseline. It did not correlate with absolute CD4
T-cell count increase. Height z score increase did not
correlate with CD4 T-cell z score or with absolute CD4
T-cell counts.
Growth and previous NRTI treatment. The height z
score decrease from week 48 to baseline was signifi-
cantly larger in naive than in pretreated patients. The
weight and BMI z score change from week 48 to base-
line was not significantly different for pretreated and
naive patients. From baseline to week 96, the height and
weight z score change increased significantly in naive
patients but not in pretreated patients compared with the
change from week 48 to baseline. The BMI z score did
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not change significantly over 96 weeks of HAART for
naive or pretreated patients.
Growth and clinical stage of infection. The clinical
stage of infection according to the Centers for Disease
Control and Prevention classification correlated nega-
tively with the BMI z score and the weight z score at
baseline but not with the height z score. Thus, children
with the most severe clinical disease had the lowest BMI
and weight z scores at baseline. The BMI z score in-
creased more in children with more advanced clinical
infection at baseline, who had lower BMI at baseline.
The clinical stage of infection did not correlate with the
change in weight z score from baseline to week 96.
Conclusions. HAART has a positive influence effect
on the growth of HIV-1–infected children. This effect is
sustained for at least 96 weeks. Height and weight are
favorably influenced in children in whom HAART leads
to a reduction of the viral load of at least 1.5 log or to
<500 copies/mL and to an increase in the CD4 T-cell z
score. In contrast to the increase of the BMI in adults on
HAART, BMI did not increase in all children effectively
treated with HAART. BMI increased more in children
with an advanced stage of infection and a poor nutri-
tional status at baseline. Data from pretreated and naive
patients were difficult to interpret, because the baseline
characteristics of these 2 groups differed too much.
Pediatrics 2002;109(2). URL: http://www.pediatrics.org/
cgi/content/full/109/2/e25; human immunodeficiency virus,
acquired immunodeficiency syndrome, highly active anti-
retroviral therapy, protease inhibitor, growth, height,
weight, body mass index.
ABBREVIATIONS. HIV-1, human immunodeficiency virus type 1;
AIDS, acquired immunodeficiency syndrome; BMI, body mass
index; HAART, highly active antiretroviral therapy; NRTI, nucle-
oside analogue reverse transcriptase inhibitor; SD, standard devi-
ation.
Growth failure is a common feature of childrenwith human immunodeficiency virus type 1(HIV-1) infection.1–8 The cause of this HIV-1-
related growth failure is complex. It is not only
caused by an inadequate caloric intake, because in-
creases in caloric intake do not seem to increase lean
body mass or accelerate the rate of linear growth, but
only increase weight and fat mass.9,10 A correlation
with viral load was previously recognized.11 Abnor-
mal function of the thyroid gland, the somatomedine
axis, the lipid metabolism, and abnormal resting en-
ergy expenditure may also contribute to the dimin-
ished growth.12,13 Growth seems to be one of the
most sensitive indicators of disease progression in
children with acquired immunodeficiency syndrome
(AIDS). The absence of growth indicates a poor prog-
nosis, also in children who are treated with antiret-
roviral regimes.14–19 Poor growth commonly pre-
cedes a decline in CD4 T-cell count and the
subsequent development of opportunistic infec-
tions.20,21 Several studies have shown that weight
gain may be an important indicator of antiretroviral
therapeutic efficacy.22,23 Children who are treated
with mono or dual therapy containing zidovudine,
didanosine, or zalcitabine show a temporary increase
in weight gain and linear growth rate.24–26 In adults,
protease-inhibitor-containing antiretroviral therapy
is associated with a sustained weight gain and in-
creased body mass index (BMI).27 Experience with
protease inhibitors and growth in children is still
limited; it mainly consists of short-term effects on
growth.28–31 The objective of this study was to eval-
uate the effect of highly active antiretroviral therapy
(HAART) consisting of 1 protease inhibitor and 2
nucleoside analog reverse transcriptase inhibitors
(NRTIs) on the long-term growth profile of HIV-1–
infected children.
METHODS
Selected growth parameters, clinical data, and laboratory re-
sults were analyzed as part of a prospective, open, uncontrolled,
multicenter study to evaluate the clinical, immunologic, and viro-
logic response to HAART consisting of indinavir, zidovudine, and
lamivudine in children with HIV-1 infection.32 The study protocol
was approved by the medical ethical committees of all the partic-
ipating centers. Written informed consent was obtained from par-
ents or legal guardians. Children 3 months of age with HIV-1
infection and 1 of the following 2 items: a decreased CD4 T-cell
count (1 year: 1750/mm3, 1–2 years: 1000/mm3, 3–6 years:
750/mm3, 6 years: 500/mm3) or a HIV-1 viral load 5000
copies/mL were included. Growth data before HAART initiation
also needed to be available to be included. Height and weight
measurements and blood samples for virologic and immunologic
parameters were obtained twice within a month before the start of
HAART, and after 12, 24, 36, 48, 60, 72, 84, and 96 weeks of
treatment. Height and weight measurements were obtained by a
single investigator using the same scales and the same metal mea-
suring rod every time. Information about the children’s growth be-
fore enrollment in the study was retrieved from the hospital medical
records and/or the school doctor or health center. Height and weight
measurements obtained closest to 24 and 48 weeks before HAART
initiation were entered into the database.
Virologic responders were defined as those who either reached
an undetectable viral load (500 copies/mL) or had a 1.5 log
reduction in viral load compared with baseline at week 12 after the
initiation of HAART, which was maintained during the follow-up
period.
The BMI was calculated from height and weight values as
defined by BMI  weight (kg)/(height (m)).2 BMI provides an
indication of the nutritional status of the patients. Compared with
the 2 other measurements for weight-for-height, ie, kg/m and
kg/m3, BMI has the desired lower correlation with height and
higher correlation with weight and skinfold thickness.33 z Scores
were used to express the deviation in standard deviation (SD)
units from the Dutch reference curves for age and gender.34,35 The
z scores for weight, height, and BMI were calculated by means of
the SDS software program (version 2.0, Erasmus University, Rot-
terdam, the Netherlands). Reference growth curves were not
available for most countries from which the patients originated.
Therefore, Dutch reference growth curves were used. Because we
only discuss change in z scores over time and not absolute z scores,
this does not present any problems. z Scores were also calculated
for CD4 T-cell counts to correct for age-related differences.36 A z
score of 0 represents the P50, which is exactly the age/sex-appro-
priate median. A height z score of 1 indicates that a child’s
height is 1 SD below the age- and gender-specific median height
for the normal population.
The viral load was measured using the Roche Amplicor HIV-1
Monitor test (Roche, Branchburg, NJ).37 CD4 T-cell counts were
obtained by standard flow cytometric methods. Statistical calcu-
lations were performed with the SPSS statistical analysis software
program (SPSS Inc, Chicago, IL, version 10.0). The relations be-
tween growth parameters, CD4 T lymphocyte counts, CD4 z
scores, and viral loads were analyzed using the Wilcoxon signed-
rank test, Mann-Whitney U test, and Spearman rank correlation
test. All P values are 2-tailed.
RESULTS
Population Characteristics
Patients
Twenty-four HIV-1–infected children were in-
cluded. They all completed at least 96 weeks of
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HAART. Baseline characteristics of these 24 children
are presented in Table 1. The median age of the
children was 5.2 years (range: 4.6 months–16.3
years). Eleven patients were not previously treated
and 13 had received previous treatment with NRTIs,
mostly zidovudine mono therapy for an average of
30 months (range: 8.4–106.2 months). Pretreated chil-
dren were significantly older at baseline than NRTI-
naive children (P  .002), with a median age of 7.4
years and 2.0 years, respectively. Twenty children
received HAART containing indinavir and 2 NRTIs
and 4 children received HAART containing nelfina-
vir and 2 NRTIs. In 5 children, indinavir was
changed to nelfinavir and in 1 child to indinavir and
ritonavir and later to nevirapine because of a viral
load rebound after a median duration of 48 weeks. In
2 other children, indinavir was changed to nelfinavir
because of long-term side effects.
Virologic Response
The median baseline plasma viral load of 5.03 log10
copies/mL (range: 2.43–5.88) decreased to less than
2.70 log10 copies/mL by week 48 and remained be-
low the level of detection until at least week 96. In
patients naive to NRTIs (N  11) median baseline
viral loads were significantly higher than in pre-
treated patients (N 13; P .02). However, at weeks
48 and 96, there was no significant difference be-
tween the viral loads of both groups (Table 2).
Seventeen children were virologic responders and
7 children virologic nonresponders.
Immunologic Response
Absolute CD4 T-cell counts per age group are
shown in Fig 1A. The median baseline CD4 T-cell z
score was 2.28 SD (range: 13.75–0.26). At base-
line, there was no significant difference between vi-
rologic responders and nonresponders or between
naive and pretreated patients (P  .05). During 96
weeks of HAART, the increase of CD4 T-cell z score
was significantly higher in responders than in non-
responders (P  .008; Fig 1B). The increase in CD4
T-cell z score was not significantly different for naive
and pretreated patients (P  .05).
Height, Weight, and BMI z Score Changes
Using data from all patients regardless of virologic
response and previous treatment, the effects of
HAART on growth were determined. We found that
the height z score decreased in the 48 weeks before
HAART initiation with a median (range) of 0.088
SD (1.88–1.17) to a median of 1.22 SD at baseline.
From baseline to 96 weeks after the initiation of
HAART the height z score increased with a median
(range) of 0.20 SD (0.72–1.29) to a median of 0.95
SD. The weight z score decreased from week 48 to
baseline with a median (range) of0.041 SD (4.10–
1.96) to a median of 0.74. From baseline to week 96
the weight z score increased with a median of 0.34 SD
(0.83–2.13) to a median of 0.60. The BMI z score
change from week 48 to baseline decreased with a
median (range) of0.12 SD (4.10–1.96) to a median
of 0.32 SD. From baseline to week 96 the median
(range) BMI z score change was 0.28 SD (1.75–3.60)
to a median of 0.19 SD. We found that there was a
trend toward a significantly increased z score change
during 96 weeks of HAART compared with the z
score change before HAART initiation for height
(P  .052) and weight (P  .056), but not for BMI
(P  .627).
Growth and Virologic Response to HAART
The median change in height z score decreased in
the 48 weeks before HAART initiation. Children with
a higher viral load at baseline showed a larger de-
crease (P  .0001) of the height z score in the 48
weeks before HAART initiation than children with a
lower viral load. From baseline to week 96 height z
score and weight z score changes increased signifi-
cantly in virologic responders, but not in nonre-
sponders compared with the change from week 48
to baseline (Fig 2A–D).
BMI z score did not increase significantly over 48
or 96 weeks of HAART in responders or in nonre-
sponders. (Fig 2, E and F) However, the BMI z score
change increased significantly more in virologic re-
sponders than in nonresponders to HAART (P .024
after 96 weeks).
Growth and Immunologic Response to HAART
During 96 weeks of HAART, the change in height
z scores from baseline did not correlate with the
change in CD4 T-cell z scores or absolute CD4
T-cell counts.
The change in weight z scores from baseline cor-
related positively with the change in CD4 T-cell z
scores at week 24 (r 0.693; P .0001), 36 (r 0.543;
P  .007), 48 (r  0.628; P  .001), 60 (r  0.540; P 
.009), 84 (r  0.496; P  .019) and 96 (r  0.408; P 
.048). The change in weight z scores only correlated
TABLE 1. Baseline Characteristics of Study Patients (n  24)
Median age in years (range) 5.2 (0.4–16.3)
Sex (male/female), n 11/13
Race/ethnicity, n
Nonwhite 19
White 5
Route of acquisition, n
Vertical 16
Blood products 4
Unknown 4
CDC classification*, n
N 1/2 2/3
A 1/2/3 2/3/4
B 1/2 1/4
C 2/3 2/3
No previous treatment, n 11
Previous treatment with, n
zidovudine 11
zidovudine/zalcitabine 2
Log10 copies of HIV RNA/mL plasma,
median (range)
5.03 (3.42–5.87)
CD4 cell count in 109/L, median
(range)
0.586 (0.010–3.580)
CD4 z score in SD, median
(range)
2.28 (13.75–0.26)
z Score in SD, median (range)
Height 1.22 (3.84–1.25)
Weight 0.74 (3.13–2.26)
BMI 0.32 (3.88–2.03)
* Clinical and immunologic categories as defined by the US Cen-
ters for Disease Control and Prevention (CDC).38
http://www.pediatrics.org/cgi/content/full/109/2/e25 3 of 7
 at Erasmus Rotterdam on November 20, 2006 www.pediatrics.orgDownloaded from 
with the change in absolute CD4 T-cell counts at
week 36 (r  0.439; P  .032).
The change in BMI z scores correlated positively
with the change in CD4 T-cell z scores at al time
points from week 12 onwards except at week 84:
week 12 (r  0.476; P  .019), 24 (r  0.671; P 
.0001), 36 (r  0.508; P  .011), 48 (r  0.592; P 
.003), 60 (r 0.443; P .039), 72 (r 0.520; P .013),
84 (r  0.369; P  .091) and 96 (r  0.501; P  .013).
The change in BMI z scores did not correlate with
change in absolute CD4 T-cell counts.
Growth and Previous NRTI Treatment
The height z score decrease from week 48 to
baseline was significantly larger in naive (0.41 SD)
than in pretreated (0.04 SD) patients (P  .007).
From baseline to week 96, the height z score change
increased significantly in naive patients (P  .033)
but not in pretreated patients compared with the
change from week 48 to baseline.
The weight and BMI z score change from week
48 to baseline was not significantly different for
pretreated and naive patients. The weight z score
change increased significantly over 96 weeks of
HAART for naive patients (P  .026) but not for
pretreated patients.
The BMI z score did not change significantly over
96 weeks of HAART for naive or pretreated patients.
There was no significant difference between naive
and pretreated patients either.
Growth and Clinical Stage of Infection
The clinical stage of infection according to the
Centers for Disease Control and Prevention classifi-
cation38 correlated negatively with the BMI z score at
baseline. Thus, children with the most severe clinical
disease had the lowest BMI z scores at baseline. The
BMI z score increased more in children with more
advanced clinical infection at baseline, who had
lower BMI at baseline.
The clinical stage of infection at baseline also cor-
related negatively with weight z score but not with
the height z score. Children with advanced clinical
infection had lower weight for their age and gender
at baseline. The clinical stage of infection did not
correlate with the change in weight z score from
baseline to week 96 (P  .05).
DISCUSSION
The results of this study indicate that children with
HIV-1 infection show a trend to an increase in height
and weight (P .052, P .056, respectively) after the
initiation of HAART. However, when the children
were divided into virologic responder and nonre-
sponder groups, the responders showed significant
increases in height and weight, whereas nonre-
sponders did not. The BMI did not change signifi-
cantly in responders or in nonresponders, although it
increased more in responders than in nonresponders.
Increasing CD4 T-cell counts favorably influenced
weight and BMI. Clinical stage of infection was also
correlated with the increase of BMI from baseline to
week 96 of HAART. BMI z scores increased more in
children with an advanced clinical stage of infection
at initiation of HAART. The energy expenditure pre-
viously needed to combat infection was possibly
used for catch-up growth. CD4 T-cell z scores then
relate to BMI and weight only indirectly.
In HIV-1–infected adults receiving HAART, BMI
Fig 1. A, CD4 T-cell count change in different age categories
during 96 weeks of HAART. B, CD4 T-cell z score change in
responders and nonresponders during 96 weeks of HAART.
TABLE 2. Viral Load at Baseline, 48 Weeks and 96 Weeks after HAART Initiation in Log copies per mL, Median (25th and 75th
Percentile)
Patients Baseline Week 48 Week 96
All 5.03 (4.29–5.60) 2.70 (2.70–2.70) 2.70 (2.70–3.29)
Naive 5.41 (5.16–5.85)* 2.70 (2.70–2.70) 2.70 (2.70–2.85)
Pretreated 4.47 (4.09–4.93)* 2.70 (2.70–2.76) 2.70 (2.70–3.47)
Responders 5.16 (4.32–5.66) 2.70 (2.70–2.70)† 2.70 (2.70–2.70)‡
Nonresponders 4.94 (4.24–5.29) 2.70 (2.70–3.80)† 3.29 (3.08–4.34)‡
* Significant difference, P  .02.
† Significant difference, P  .024.
‡ Significant difference, P  .0001.
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increased significantly more in responders than in
nonresponders, but BMI also increased significantly
overall in responders and in nonresponders. BMI
increase consisted mainly of increased fat mass. Lean
body mass did not increase significantly.27 We are
not aware of any previously published studies on the
influence of HAART on BMI in HIV-1–infected chil-
dren. However, in a recent study in HIV-1–infected
children, protease inhibitors were found to cause a
significant increase in weight-for-height and a dra-
matic improvement in lean body mass over a short
interval and had no immediate influence on fat mass,
although there was a trend toward increased fat
mass, with longer follow-up time.28 This suggests
that in the children whose BMI increased in our
study, namely the children with an advance stage of
clinical infection and responders to HAART with a
high increase in CD4 T-cell count, lean body mass
also increased. The difference of the effect of HAART
on body composition between children and adults
could be attributed to the fact that children are still
growing so their metabolism is different, but addi-
tional research is needed.
Height did not increase significantly in responders
until week 96, whereas weight already increased sig-
nificantly at week 48. This is a normal reaction to the
correction of a growth-retarding disorder: catch-up
growth first affects weight followed by height.39
At the initiation of HAART, viral loads correlated
negatively with height z score change in the previous
year and the clinical stage of infection correlated
negatively with BMI z score and weight z score.
Children with high viral loads and severe clinical
infection also had poor grow parameters. These are
all associated with a poor prognosis. Although the
number or percentage of CD4 T cells has a larger
influence on prognosis, increasing growth rates also
contribute to a better prognosis.16,18,19,22,23
Height and weight z score change over 96 weeks
compared with z score change in the 48 weeks before
HAART initiation increased more in responders than
in nonresponders. It also increased more in naı¨ve
patients than in pretreated patients. Although this
could be interpreted as a confounder, it is more likely
to be the result of previous antiretroviral therapy.
Pretreated patients seem to have already reached a
Fig 2. Growth before and during HAART in (A, C, and E) responders and (B, D, and F) nonresponders.
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higher height z score change during the 48 weeks
before HAART initiation. This may have been caused
by the treatment with NRTIs. Weight z score change
in the 48 weeks before HAART initiation was not
significantly different between naive and pretreated
patients. We concluded from the observation that
weights increased in naive patients and not in pre-
treated patients. However, a difference was observed
in baseline viral load and age: pretreated patients
were significantly older and had a significantly
lower viral load. This complicates the comparison
between these 2 groups of patients.
Similar results in height and weight gain as ob-
served by our group were reported in 3 other studies
on the effects of HAART in children.28,30,31 However,
the follow-up time of these studies was only 24
weeks. A positive influence on growth has been ob-
served as a result of NRTI mono therapy or dual
therapy during this same period.14,22,24,40–46 The ef-
fect on growth of mono therapy cannot be sustained
after 24 weeks of treatment. There is no data that
supports that dual therapy has a sustained effect on
growth beyond 24 weeks. The current study shows
that the positive effects of HAART on growth can be
sustained for at least 96 weeks. Therefore, the effect
on growth lasts longer in patients receiving HAART
than in patients receiving mono or duo reverse tran-
scriptase inhibitor therapy. There seems to be a rela-
tion between the time that an antiretroviral therapy
is successful in the suppression of viral load and the
time that the positive effect on growth by this ther-
apy can be maintained. Ogino et al22 also raised this
point when they described the effect of zidovudine
resistance on growth.
Dreimane et al29 retrospectively reviewed 27 HIV-
1–infected children receiving HAART for a mean
follow-up time of 20 months. They also found in-
creased z scores for height and height-velocity, but
not for weight. This difference in findings may be
attributed to the low number of responders to
HAART in their study (10 of 27) compared with the
high number of responders (17 of 24) in our study. It
could also be attributed to the fact that they used
another protease inhibitor. Unfortunately, they did
not mention which protease inhibitor was used in
their patients. Miller et al28 found that ritonavir had
a weaker effect on weight with a stronger effect on
height compared with indinavir and nelfinavir.
CONCLUSION
HAART has a positive effect on height and weight
in children with HIV-1 infection. This effect is sus-
tained for at least 96 weeks and is associated with the
successful application of HAART, resulting in long-
term viral load reduction of at least 1.5 log cop-
ies/mL or viral load suppression below 500 cop-
ies/mL and an increase of CD4 T-cell counts. The
sustained effects of HAART on growth may posi-
tively influence the child’s quality of life and will
predictably contribute to a better prognosis. The
mechanism of increased growth during antiretrovi-
ral therapy is yet unknown. Contrary to the BMI
increase in adults treated with HAART, BMI in chil-
dren does not increase in all patients successfully
treated with HAART, but only in those with a low
BMI at initiation of HAART. More research is needed
to investigate whether those factors causing growth
failure in children with HIV-1 infection—caloric in-
take, thyroid and growth hormones, lipid metabo-
lism, and resting energy expenditure—also play a
role in the recovery of growth parameters during
HAART.
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